Month: January 2017

Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform

Macrophage Pharma Limited, a newly formed immune-oncology company, today announced that it has successfully raised £9 million in a Series A equity financing round. The Company has also acquired global rights to a novel technology platform, Esterase Sensitive Motif (ESM), from Chroma Therapeutics Limited (Oxford, UK) together with discovery stage therapeutic assets. Macrophage Pharma was … Continue reading “Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform”